• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?老年患者与程序性死亡受体1配体1（PD-L1）阳性的晚期非小细胞肺癌：帕博利珠单抗单药治疗是否有效且安全？
Ann Transl Med. 2019 Dec;7(Suppl 8):S282. doi: 10.21037/atm.2019.12.31.
2
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
3
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.一线帕博利珠单抗单药治疗高龄（≥75 岁）非小细胞肺癌患者的疗效和安全性。
J Cancer Res Clin Oncol. 2020 Feb;146(2):457-466. doi: 10.1007/s00432-019-03072-1. Epub 2019 Dec 18.
4
Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study.帕博利珠单抗单药治疗老年或体能状态差的未经治疗的PD-L1阳性非小细胞肺癌：一项前瞻性观察研究。
Front Oncol. 2022 Sep 9;12:904644. doi: 10.3389/fonc.2022.904644. eCollection 2022.
5
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer.抗TIGIT抗体vibostolimab单药或与帕博利珠单抗联合用于包括非小细胞肺癌在内的晚期实体瘤的首次人体1期研究。
Ann Oncol. 2022 Feb;33(2):169-180. doi: 10.1016/j.annonc.2021.11.002. Epub 2021 Nov 18.
6
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.PD-L1 表达指导下信迪利单抗对比帕博利珠单抗联合或不联合铂类双药化疗用于未经治疗的晚期非小细胞肺癌患者（CTONG1901）：一项随机、对照、开放的 2 期临床研究。
Sci Bull (Beijing). 2024 Feb 26;69(4):535-543. doi: 10.1016/j.scib.2023.12.046. Epub 2023 Dec 26.
7
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.预处理格拉斯哥预后评分预测 PD-L1 高表达患者接受一线帕博利珠单抗单药治疗非小细胞肺癌的生存情况。
Cancer Med. 2021 Oct;10(20):6971-6984. doi: 10.1002/cam4.4220. Epub 2021 Aug 20.
8
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.伊沃西单抗对比帕博利珠单抗治疗PD-L1阳性非小细胞肺癌（HARMONi-2）：一项在中国开展的随机、双盲、3期研究
Lancet. 2025 Mar 8;405(10481):839-849. doi: 10.1016/S0140-6736(24)02722-3.
9
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
10
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.TROPION-Lung08：达泊妥单抗德鲁替康联合帕博利珠单抗作为晚期非小细胞肺癌一线治疗的III期研究。
Future Oncol. 2023 Jul;19(21):1461-1472. doi: 10.2217/fon-2023-0230. Epub 2023 May 30.

引用本文的文献

1
Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.关于一线免疫检查点抑制剂或与化疗联合用于老年（年龄≥75岁）晚期非小细胞肺癌患者的真实世界数据。
Heliyon. 2024 Feb 11;10(4):e26026. doi: 10.1016/j.heliyon.2024.e26026. eCollection 2024 Feb 29.
2
Narrative review of immunotherapy and radiation therapy in elderly patients.老年患者免疫治疗与放射治疗的叙述性综述
Transl Cancer Res. 2021 May;10(5):2620-2631. doi: 10.21037/tcr-20-2637.
3
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database.一线帕博利珠单抗治疗PD-L1阳性老年非小细胞肺癌的有效性和安全性：艾伯塔省免疫治疗数据库的一项回顾性队列研究
Curr Oncol. 2021 Oct 18;28(5):4213-4222. doi: 10.3390/curroncol28050357.

本文引用的文献

1
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
2
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis.比较老年和年轻晚期或转移性肺癌患者免疫检查点抑制剂的疗效：一项系统评价和荟萃分析。
Biomed Res Int. 2019 May 13;2019:9853701. doi: 10.1155/2019/9853701. eCollection 2019.
3
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.帕博利珠单抗治疗晚期非小细胞肺癌患者的 5 年总生存结果：来自 I 期 KEYNOTE-001 研究的结果。
J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.
4
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).纳武利尤单抗治疗晚期非小细胞肺癌患者的安全性、疗效以及患者报告的健康相关生活质量和症状负担，包括 70 岁或以上或体能状态不佳的患者（CheckMate 153）。
J Thorac Oncol. 2019 Sep;14(9):1628-1639. doi: 10.1016/j.jtho.2019.05.010. Epub 2019 May 20.
5
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
6
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.
7
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
8
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.FDA 对 PD-1/PD-L1 阻断抗体临床试验中转移性非小细胞肺癌老年患者生存情况的分析。
Semin Oncol. 2018 Aug;45(4):220-225. doi: 10.1053/j.seminoncol.2018.08.007. Epub 2018 Oct 31.
9
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.PD-1 和 PD-L1 抑制剂在老年患者中的疗效：一项荟萃分析。
J Immunother Cancer. 2018 Apr 4;6(1):26. doi: 10.1186/s40425-018-0336-8.
10
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.

Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?

作者信息

Gridelli Cesare, Sgambato Assunta

机构信息

Division of Medical Oncology, "S. G. Moscati" Hospital, Avellino, Italy.

出版信息

Ann Transl Med. 2019 Dec;7(Suppl 8):S282. doi: 10.21037/atm.2019.12.31.

DOI:10.21037/atm.2019.12.31
PMID:32016001
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6976439/
Abstract
摘要